Switch theme
Sign up to access all valuation multiples
Sugi Holdings Co Ltd generates revenue through pharmaceutical care in Japan. The company's drug stores sell prescription and generic drugs along with general merchandise including premium and discount groceries, discount cosmetics, pet supplies, and health supplements that are designed for self-medication. Sugi Holdings also provides disease prevention and drug delivery services. The company's Cedar Pharmacy group operates regional drugstores designed for providing health consultation. Sugi Holdings also supports regional healthcare facilities and provides at-home nursing services.
1982
14.3K+
LTM Revenue $6.2B
LTM EBITDA $428M
$3.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sugi Holdings has a last 12-month revenue (LTM) of $6.2B and a last 12-month EBITDA of $428M.
In the most recent fiscal year, Sugi Holdings achieved revenue of $6.0B and an EBITDA of $386M.
Sugi Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sugi Holdings valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.2B | XXX | $6.0B | XXX | XXX | XXX |
| Gross Profit | $2.0B | XXX | $1.9B | XXX | XXX | XXX |
| Gross Margin | 31% | XXX | 31% | XXX | XXX | XXX |
| EBITDA | $428M | XXX | $386M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| EBIT | $302M | XXX | $292M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $188M | XXX | $176M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sugi Holdings's stock price is JPY 3168 (or $22).
Sugi Holdings has current market cap of JPY 573B (or $3.9B), and EV of JPY 566B (or $3.9B).
See Sugi Holdings trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.9B | $3.9B | XXX | XXX | XXX | XXX | $1.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sugi Holdings has market cap of $3.9B and EV of $3.9B.
Sugi Holdings's trades at 0.7x EV/Revenue multiple, and 10.4x EV/EBITDA.
Equity research analysts estimate Sugi Holdings's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sugi Holdings has a P/E ratio of 20.9x.
See valuation multiples for Sugi Holdings and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.9B | XXX | $3.9B | XXX | XXX | XXX |
| EV (current) | $3.9B | XXX | $3.9B | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.1x | XXX | 10.4x | XXX | XXX | XXX |
| EV/EBIT | 12.9x | XXX | 13.6x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.9x | XXX | 22.9x | XXX | XXX | XXX |
| EV/FCF | 62.7x | XXX | 55.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSugi Holdings's last 12 month revenue growth is 12%
Sugi Holdings's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Sugi Holdings's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sugi Holdings's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sugi Holdings and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 18% | XXX | 18% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sugi Holdings acquired XXX companies to date.
Last acquisition by Sugi Holdings was XXXXXXXX, XXXXX XXXXX XXXXXX . Sugi Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sugi Holdings founded? | Sugi Holdings was founded in 1982. |
| Where is Sugi Holdings headquartered? | Sugi Holdings is headquartered in Japan. |
| How many employees does Sugi Holdings have? | As of today, Sugi Holdings has 14.3K+ employees. |
| Is Sugi Holdings publicy listed? | Yes, Sugi Holdings is a public company listed on TKS. |
| What is the stock symbol of Sugi Holdings? | Sugi Holdings trades under 7649 ticker. |
| When did Sugi Holdings go public? | Sugi Holdings went public in 2001. |
| Who are competitors of Sugi Holdings? | Similar companies to Sugi Holdings include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Sugi Holdings? | Sugi Holdings's current market cap is $3.9B |
| What is the current revenue of Sugi Holdings? | Sugi Holdings's last 12 months revenue is $6.2B. |
| What is the current revenue growth of Sugi Holdings? | Sugi Holdings revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Sugi Holdings? | Current revenue multiple of Sugi Holdings is 0.6x. |
| Is Sugi Holdings profitable? | Yes, Sugi Holdings is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sugi Holdings? | Sugi Holdings's last 12 months EBITDA is $428M. |
| What is Sugi Holdings's EBITDA margin? | Sugi Holdings's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Sugi Holdings? | Current EBITDA multiple of Sugi Holdings is 9.1x. |
| What is the current FCF of Sugi Holdings? | Sugi Holdings's last 12 months FCF is $61.9M. |
| What is Sugi Holdings's FCF margin? | Sugi Holdings's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Sugi Holdings? | Current FCF multiple of Sugi Holdings is 62.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
